The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial ...

Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of ...

ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies will air interviews with Connect Biopharma Holdings Limited (Nasdaq:CNTB) and Bimergen Energy Corp. (OCTQB:BESS) on the RedChip ...

Background Bronchoscopic limitations in reaching peripheral pulmonary lesions (PPLs) can compromise biopsy sensitivity, ...

Mid Yorkshire Teaching NHS Trust has become the first site in Europe to recruit a patient to a major international clinical ...

Jefferies London Healthcare Conference 2025 November 19, 2025 4:30 AM ESTCompany ParticipantsTony Wood - Chief Scientific Officer and Head ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Nov. 17th: Roku ROKU ...

The article " Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything " first appeared on MarketBeat.

A Scotland-based drug delivery device developer has secured an additional £1.5 million in seed funding to drive development ...

Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and ...